Advertisement

Detection of Driver and Subclonal Mutations in Myelofibrosis: Clinical Impact on Pharmacologic and Transplant-Based Treatment Strategies

The presence of molecular markers might offer the possibility to evaluate the depth of remission and to monitor minimal residual disease after transplantation.

 Expert Rev Hematol